@article{oai:repo.qst.go.jp:00076482,
 author = {花岡, 宏史 群馬大学大学院医学系研究科 and Oshima, Yasuhiro and 山口, 藍子 群馬大学大学院医学系研究科 and 鈴木, 博元 千葉大学大学院薬学研究院 and Ishioka, Noriko and 樋口, 徹也 群馬大学大学院医学系研究科 and 荒野, 泰   千葉大学大学院薬学研究院 and 対馬, 義人 群馬大学大学院医学系研究科 and Oshima, Yasuhiro and Ishioka, Noriko},
 issue = {8},
 journal = {Molecular Pharmaceutics},
 month = {Jul},
 note = {Positron emission tomography (PET) imaging with 18F-labeled α-methyl-substituted amino acids exerts significant influence on differential diagnosis of malignant tumors and tumor-like lesions. We newly designed 18F-labeled α-methyl-phenylalanine (18F-FAMP) regioisomers (2-, 3-, or 4-18F-FAMP) and stereoisomers (L- or D-form), and we evaluated their potential as tumor-imaging agents. In tumor bearing mice, L-2-18F-FAMP exhibited significantly higher tumor accumulation than the D-18F-FAMPs or a clinically relevant tracer, L-3-18F-α-methyl-tyrosine (18F-FAMT) (p < 0.05). Specificity of L-2-18F-FAMP for L-type amino acid transporter-1, a tumor-specific transporter, was validated in the cellular uptake studies. The PET imaging with L-2-18F-FAMP clearly visualized the tumor as early as 1 h after injection, and the high tumor accumulation level was retained for 3 h. These findings suggest that L-2-18F-FAMP constitutes a potential PET tracer for tumor-specific imaging.},
 pages = {3609--3616},
 title = {Novel 18F‑Labeled α‑Methyl-Phenylalanine Derivative with High Tumor Accumulation and Ideal Pharmacokinetics for Tumor-Specific Imaging},
 volume = {16},
 year = {2019}
}